Fifteen RCTs (n=5,200 participants, range 99 to 1,172) were included.
Aripiprazole (one RCT), olanzapine alone (one RCT), quetiapine alone or in combination (three RCTs), risperidone long-acting injection (two RCTs), lithium alone or in combination (six RCTs), lamotrigine (two RCTs) and divalproex in combination (three RCTs) were significantly superior to placebo for prevention of relapse into any mood episode (all ≥10% advantage over placebo) based on NNT.
Quetiapine alone or in combination (three RCTs), lithium (six RCTs), risperidone long-acting injection (two RCTs), aripiprazole (one RCT) and olanzapine (one RCT) were significantly superior to placebo in manic recurrence prevention based on NNT.
Lamotrigine (one RCT), quetiapine alone or in combination (three RCTs) and lithium (one RCT) were significantly superior to placebo for prevention of depressive relapses based on NNT.